The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial - Lerario, A M; Worden, F P; Ramm, C A (Horm Cancer, 2014)
et al.